English
Back
Open Account
港股窩輪Jenny
wrote a column · Mar 26 14:41

China Life (2628) plunges to new lows, does technical divergence hint at a rebound opportunity?

$CHINA LIFE (02628.HK)$ Following the earnings disclosure, the stock price plummeted over 9%, hitting an intraday low of 24.82 yuan, marking the lowest level since November 2025. The current stock price has broken below key moving averages: the 10-day (27.63 yuan), 30-day (30.18 yuan), and 60-day (31.23 yuan) lines, placing it in a clear downtrend channel. On the price front, the primary support is at 24.1 yuan; if this level fails, the next line of defense will be at 22.4 yuan. Initial resistance for a rebound is located at 28.1 yuan (close to the 10-day moving average), with stronger resistance at 33.2 yuan. These price levels are critical nodes for observing short-term movements.
Technical indicators show significant structural divergence: trend-based indicators remain bearish overall, with MACD issuing a sell signal, confirming that the bearish pattern remains dominant. However, oscillation-based indicators have continuously released positive signals—RSI dropped to 35, entering the oversold zone, while stochastic oscillators and Williams %R also confirmed an oversold state. Both CCI and momentum oscillators issued 'buy' signals, indicating that short-term downward momentum has been overly exhausted, suggesting a need for technical recovery.
Overall, the market is currently caught between 'weak trends' and 'oversold momentum.' Although the intermediate-term bearish trend remains intact, multiple oscillation indicators entering the oversold region simultaneously increase the probability of a technical rebound near support levels to 54%. At current prices, blindly shorting is not advisable. Operationally, focus on observing stop-loss signals in the 24.1-22.4 yuan support zone. If stabilization occurs, a light position can be taken for a short-term rebound, targeting initial resistance at 28.1 yuan, with a strict stop-loss set at 22.4 yuan. A breach below would further confirm the weak trend.
$CHINA LIFE (02628.HK)$ Following the earnings disclosure, the stock price plummeted over 9%, hitting an intraday low of 24.82 yuan, marking the lowest level since November 2025. The current stock price has broken below key moving averages: the 10-day (27.63 yuan), 30-day (30.18 yuan), and 60-day (31.23 yuan) lines, placing it in a clear downtrend channel. On the price front, the primary support is at 24.1 yuan; if this level fails, the next line of defense will be at 22.4 yuan. Initial resistance for a rebound is located at 28.1 yuan (close to the 10-day moving average), with stronger resistance at 33.2 yuan. These price levels are critical nodes for observing short-term movements. Technical indicators show significant structural divergence: trend-based indicators remain bearish overall, with MACD issuing a sell signal, confirming that the bearish pattern remains dominant. However, oscillation-based indicators have continuously released positive signals—RSI dropped to 35, entering the oversold zone, while stochastic oscillators and Williams %R also confirmed an oversold state. Both CCI and momentum oscillators issued 'buy' signals, indicating that short-term downward momentum has been overly exhausted, suggesting a need for technical recovery. Overall, the market is currently caught between 'weak trends' and 'oversold momentum.' Although the intermediate-term bearish trend remains intact, multiple oscillation indicators entering the oversold region simultaneously increase the probability of a technical rebound near support levels to 54%. At current prices, blindly shorting is not advisable. Operationally, focus on observing stop-loss signals within the 24.1-...
$CHINA LIFE (02628.HK)$ Following the earnings disclosure, the stock price plummeted over 9%, hitting an intraday low of 24.82 yuan, marking the lowest level since November 2025. The current stock price has broken below key moving averages: the 10-day (27.63 yuan), 30-day (30.18 yuan), and 60-day (31.23 yuan) lines, placing it in a clear downtrend channel. On the price front, the primary support is at 24.1 yuan; if this level fails, the next line of defense will be at 22.4 yuan. Initial resistance for a rebound is located at 28.1 yuan (close to the 10-day moving average), with stronger resistance at 33.2 yuan. These price levels are critical nodes for observing short-term movements. Technical indicators show significant structural divergence: trend-based indicators remain bearish overall, with MACD issuing a sell signal, confirming that the bearish pattern remains dominant. However, oscillation-based indicators have continuously released positive signals—RSI dropped to 35, entering the oversold zone, while stochastic oscillators and Williams %R also confirmed an oversold state. Both CCI and momentum oscillators issued 'buy' signals, indicating that short-term downward momentum has been overly exhausted, suggesting a need for technical recovery. Overall, the market is currently caught between 'weak trends' and 'oversold momentum.' Although the intermediate-term bearish trend remains intact, multiple oscillation indicators entering the oversold region simultaneously increase the probability of a technical rebound near support levels to 54%. At current prices, blindly shorting is not advisable. Operationally, focus on observing stop-loss signals within the 24.1-...
In terms of institutional ratings, several top-tier brokerages continue to maintain positive evaluations: Morgan Stanley gave the highest target price of 43.1 yuan with an 'Overweight' rating; UBS Group slightly lowered its target price from 42 yuan to 40 yuan but maintained a 'Buy' rating; Citi maintained a 40-yuan target price and a 'Buy' rating; Bank of America maintained a target price of 33.1 yuan and a 'Buy' rating; and CLSA maintained a target price of 33 yuan and an 'Outperform' rating.
CLSA noted that China Life's 2025 performance met expectations, with annual dividend payouts increasing by 32% year-over-year, exceeding guidance. The Q4 net loss stemmed from a high base and capital market adjustments, which were anticipated. The firm is optimistic about China Life’s improving equity asset allocation and sees strong growth logic driven by the bancassurance channel, clearly positioning it as a core beneficiary of tightened bank commission regulations and the deposit-to-insurance shift. Despite a slight downward revision in earnings forecasts due to A-share adjustments, they maintain an H-share target of 33 yuan and an A-share... $China Life Insurance (601628.SH)$ The target price of 45 RMB remains unchanged. Bank of America suggests downplaying the impact of the Q4 phased loss, emphasizing the high-quality attributes of a 36% growth in full-year new business value accompanied by a 10 percentage point increase in profit margins. It is expected that the new business value in the first quarter of 2026 will maintain a growth rate of 20%-30%. Short-term investment volatility does not affect long-term value, and the 'Buy' rating is maintained.
On March 20, 2026, China Life Insurance’s underlying stock fell cumulatively by 4.47% over the following two days, while corresponding bearish derivative products recorded significant increases across the board, among which $BPCLIFE@EP2605B.P (23307.HK)$ rose by 62%, $HSCLIFE@EP2605B.P (23624.HK)$ rose by 45%, $UB#CLIFERP2805I.P (53040.HK)$ rose by 29%, $SG#CLIFERP2805I.P (53704.HK)$ rose by 25%, all correctly predicting the downward trend of the underlying stock, reflecting their high leverage characteristics.
$CHINA LIFE (02628.HK)$ Following the earnings disclosure, the stock price plummeted over 9%, hitting an intraday low of 24.82 yuan, marking the lowest level since November 2025. The current stock price has broken below key moving averages: the 10-day (27.63 yuan), 30-day (30.18 yuan), and 60-day (31.23 yuan) lines, placing it in a clear downtrend channel. On the price front, the primary support is at 24.1 yuan; if this level fails, the next line of defense will be at 22.4 yuan. Initial resistance for a rebound is located at 28.1 yuan (close to the 10-day moving average), with stronger resistance at 33.2 yuan. These price levels are critical nodes for observing short-term movements. Technical indicators show significant structural divergence: trend-based indicators remain bearish overall, with MACD issuing a sell signal, confirming that the bearish pattern remains dominant. However, oscillation-based indicators have continuously released positive signals—RSI dropped to 35, entering the oversold zone, while stochastic oscillators and Williams %R also confirmed an oversold state. Both CCI and momentum oscillators issued 'buy' signals, indicating that short-term downward momentum has been overly exhausted, suggesting a need for technical recovery. Overall, the market is currently caught between 'weak trends' and 'oversold momentum.' Although the intermediate-term bearish trend remains intact, multiple oscillation indicators entering the oversold region simultaneously increase the probability of a technical rebound near support levels to 54%. At current prices, blindly shorting is not advisable. Operationally, focus on observing stop-loss signals within the 24.1-...
For call warrants, $SGCLIFE@EC2607B.C (17896.HK)$ offers approximately 4.1 times leverage with a strike price of 22 yuan. Its features include relatively higher leverage and the lowest premium among similar products, making it suitable for investors who are optimistic about the future market and wish to enter at a lower cost. Another option, $MSCLIFE@EC2606A.C (17957.HK)$ provides around 5.1 times leverage with a strike price of 22.99 yuan. Its implied volatility is one of the lowest on the market, and its higher leverage makes it suitable for investors focused on managing volatility risks.
For put warrants, $HSCLIFE@EP2605B.P (23624.HK)$ offers about 7.8 times leverage with a strike price of 22.88 yuan. Its implied volatility is relatively low, reducing the impact caused by changes in volatility. $BPCLIFE@EP2605B.P (23307.HK)$ also provides approximately 7.8 times leverage with a strike price of 22.92 yuan. Its feature is having the lowest premium among similar products, along with higher leverage, making it suitable for investors who are bearish on the future market and seek higher cost-effectiveness.
For bull certificates, $UB#CLIFERC2712B.C (64951.HK)$The actual leverage is about 5.8 times, with a recovery price of 21 dollars and the lowest premium in its category. The actual leverage is also relatively high, making it suitable for investors who are optimistic and wish to control premium costs. Another one$UB#CLIFERC2808E.C (53359.HK)$The actual leverage is about 10.6 times, with a recovery price of 23 dollars. It has high actual leverage and low premium, making it suitable for investors who can bear higher risks and seek greater leverage effects.
In terms of bear certificates,$SG#CLIFERP2805J.P (65273.HK)$The actual leverage is about 5.9 times, with a recovery price of 29 dollars. Its actual leverage is the highest in its category, and the premium is also relatively low, making it suitable for investors who are pessimistic about the future market and pursue high leverage.$UB#CLIFERP2806A.P (64795.HK)$The actual leverage is about 6 times, with the same recovery price of 29 dollars. The premium is the lowest in its category, and the actual leverage is also relatively high, making it suitable for investors who focus on low premiums and hope to effectively amplify their returns from a bearish outlook.
China Life's stock plunged over 9% after earnings were released, while other stocks that are about to announce their results$PING AN (02318.HK)$ 、 $PICC P&C (02328.HK)$ 、 $CPIC (02601.HK)$ 、 $NCI (01336.HK)$have fallen between 2-5.6%. Do you think this is an overreaction by the market or are there real concerns with the fundamentals? The support level is at 24.1 dollars. Do you think this key position will be broken within this week? Feel free to share your insights in the comments section. For more market analysis, please continue following 'Hong Kong Warrant Jenny' for daily updates!
Reminder: This article does not constitute any investment advice.
This article is for reference only and does not constitute any investment advice. The market data, opinions, and analysis contained herein may change at any time without prior notice. We are not responsible for any loss or damage caused by reliance on the information in this article. Technical analysis only shows whether certain technical conditions are met; a comprehensive assessment of asset performance should be conducted using additional data. Decisions to trade should not be based solely on this article. Please note that past performance is not indicative of future results.
#HongKongStocks #RealTimeAnalysis #WarrantsSelection #WarrantsStrategy #DerivativesHedging #HongKongWarrantsJenny #ChinaLife #02628 #InsuranceStocks #TechnicalAnalysis$Hang Seng Index (800000.HK)$$Hang Seng China Enterprises Index (800100.HK)$$Insurance (LIST1003.HK)$
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Thumbs Up
2
217K Views
Report
Comments
Write a Comment...
2
1